Case series reports trimethoprim-sulfamethoxazole treatment is safe in infants with suspected MRBP infection.
Summary Since 2023, macrolide-resistant Bordetella pertussis (MRBP) has surged worldwide. Six infants aged <2 months completed a 14-day course of trimethoprim-sulfamethoxazole for suspected MRBP infection without significant adverse events. Trimethoprim-sulfamethoxazole may be a tolerable option in infants in MRBP-dominant settings.
No takes yet. Share an insight, caveat, or question.
Ikuse et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: